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Summary Thirty-one consecutive patients with relapsed or refractory GCT received an HDT schedule including carboplatin, the dose of
which was adjusted to measured glomerular filtration rate. There was one HDT-associated death (3%), due to acute renal failure. The 3-year
probability of overall and disease-free survival for 21 patients with primary refractory disease or responsive relapse was 60% and 42%,
respectively, while none of ten patients with refractory relapse have survived disease free.
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Germ cell tumours (GCT) are among the most chemosensitive of
malignancies. With the use of platinum- and etoposide-containing
regimens at least 80% of patients with disseminated GCT at
presentation enter long-term remission with primary therapy alone
(Hitchins et al, 1989; Mead et al, 1992; Mencel et al, 1994).
However, the outcome in patients who fail to achieve an initial
complete remission (CR) or who suffer later relapse is much less
favourable (Motzer et al, 1991).
High-dose therapy (HDT) with autologous haemopoietic stem
cell support may salvage a proportion of patients who have failed
conventional-dose platinum-based chemotherapy (Broun et al,
1992; Motzer and Bosl, 1992). Previous studies of HDT have used
the combination of carboplatin with etoposide, in some cases with
the addition of an oxazaphosphorine (Nichols et al, 1992; Bamett
et al, 1993; Siegert et al, 1994). The dose of carboplatin has
commonly been calculated according to surface area (typically
1.2-1.8 g m-2). However, pharmacokinetic studies have demon-
strated that carboplatin exposure is proportional to the glomerular
filtration rate (GFR) (Calvert et al, 1989). In this study, we report
HDT in 31 patients with high-risk GCT in which the carboplatin
dose was adjusted according to GFR. We also examine the
influence of various pre-HDT parameters on eventual outcome.
PATIENTS AND METHODS
Thirty-one male patients with advanced seminoma (n = 6) or non-
seminomatous GCT (n = 25) received HDT with autologous stem
cell support. Patients were considered eligible if they had primary
refractory or relapsed disease after one or more platinum-
containing regimens. Disease status was designated (a) 'primary
refractory' if CR (no clinical or serum tumour marker evidence of
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disease maintained for at least 1 month) was never achieved after
presentation, (b) 'responsive relapse' if at least a 50% clinical or
serum tumour marker response to therapy after relapse from CR
had been documented within 3 months before HDT or (c) 'refrac-
tory relapse' if a patient, previously in CR, failed to respond to
therapy as defined in b above. Patients were not excluded from
entry to this study on the basis of renal impairment.
The chemotherapy regimen used for the HDT procedure was
modified from that previously studied at the Memorial Sloan-
Kettering Cancer Center (Motzer et al, 1993) and consisted of (a)
etoposide 600 mg m-2 on days 1, 3 and 5 (total dose 1800 mg m-2),
(b) cyclophosphamide 60 mg kg-' on days 3 and 5 (total dose
120 mg kg-') and (c) carboplatin, the dose of which was adjusted
to achieve an area under curve (AUC) of 10 mg ml-1 min-' for each
infusion on days 1, 3 and 5 (total AUC of 30), according to the
formula previously proposed and validated by Calvert et al (1989)
[carboplatin dose = AUC x (GFR + 25)]. GFR values were derived
from measurement of 5'Cr-EDTA clearance. Autologous stem
cells were reinfused 9 days after the commencement of
chemotherapy.
Events (death and disease recurrence) were calculated from the
time of autologous stem cell reinfusion. Survival curves were
generated using the Kaplan-Meier method (Kaplan and Meier,
1958), and curves were compared with log-rank statistics. Toxicity
was graded using WHO criteria.
RESULTS
Patient characteristics
Patient characteristics at presentation and at the time of HDT are
shown in Table 1, together with the corresponding characteristics
of long-term survivors (> 1.5 years) after HDT. Twenty-two of 31
patients had advanced stage (Ill or IV) disease at presentation
(Peckham, 1971), and 12 had high initial serum tumour marker
levels (HCG > 10 000 IU I-' and/or AFP > 1 000 kU I-'). At the
time of HDT, 21 of 31 patients had received three or more previous
platinum-containing regimens; 22 patients were at that stage
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Table 1 Characteristics of 31 patients receiving HDT
Characteristic All patients Long-term survivors Significance of
(n = 31) (> 1.5 years, n = 11) comparison
Disease
Teratoma 25 10
Seminoma 6 1 NS
Stage at diagnosis
1 1 0
11 6 1
III 6 3
IV 16 6
Unknown 2 1 NS
HCG at diagnosis (median 300 IU I-1)
Patients > 10 000 IU j-1 7 2 NS
AFP at diagnosis (median 22 kU 1-')
Patients> 1000 kU -1 6 2 NS
Disease status at HDT
Primary refractory 12 5
Responsive relapse 9 6
Refractory relapse 10 0 P < 0.01
Interval (years) from presentation to HDT (range 0.3-14.8, median 1.3)
Interval > 2.0 years 9 2 NS
Number of platinum-containing regimens before HDT (median 3)
One or two 10 5
Three or more 21 6 NS
Bone, brain or liver metastases at HDT 13 4 NS
NS, not significant.
Table 2 Early toxicity after HDT in 31 patients by glomerular filtration rate (GFR)
All patients GFR of median or GFR below median
greater (.75 ml min-') (< 75 ml min-')
Number of patients 31 16 15
Median GFR before HDT (ml min-', range) 75 (19-122) 91(75-122) 52 (19-73)
Grade 3-4 (WHO) mucositis 31 16 15
Acute renal failure requiring haemodialysis 3 0 3
Grade 3 (WHO) neuropathy 2 0 2
Hepatic veno-occlusive disease 2 2 0
HDT-associated mortality 1 0 1
refractory to conventional treatment (12 with primary refractory
disease and ten with refractory relapse). Two patients were in
untested relapse at the time of HDT and have been analysed with
the 'responsive relapse' group.
Renal function and carboplatin dosage
The median measured GFR before HDT was 75 ml min-' (range
19-122 ml min-1). The median total dose of carboplatin received
was 3.0 g (range 1.32-4.41 g); expressed in terms of body surface
area the median total dose received was 1.60 g m-2 (range
0.60-2.53 g m-2).
HDT-associated toxicity
Table 2 shows toxicity data with patients categorized by pre-HDT
GFR of below (n = 15) or above (n = 16) 75 ml min-', which was
the median GFR of all patients. Of note, acute renal failure (ARF)
requiring dialysis developed in three patients with pre-HDT
GFR of 19, 55 and 67 ml min-1; in one case (pre-HDT GFR of
19 ml min-'), this complication proved fatal, but was reversible in
the other two. Only one of four patients with pre-HDT GFR of less
than 40 ml min-' developed ARF. HDT-associated mortality in this
series was 1 out of 31 (3%) patients.
Outcome
Fourteen of 31 patients survive with a median follow-up of 2.9
years after HDT (range 0.6-5.2 years). The 3-year probability of
overall (OS) and disease-free (DFS) survival in these 31 patients
was 41% and 28% respectively (Figure 1). No relapses have
occurred beyond 1.3 years post HDT. Characteristics of the 11
long-term (> 1.5 years after HDT) survivors, eight of whom have
been disease-free since HDT, are shown in Table 1. Two patients
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had persistent local disease after HDT and, after surgical resection
of residual tumour, have remained in CR (follow-up of 11 and 55
months post HDT). Two other patients received further conven-
tional dose chemotherapy (and radiotherapy in one case) for relapse
after HDT and have remained in CR for an additional 17 and 42
months. These four patients have been analysed as HDT failures.
Prognostic indicators
Presentation disease stage, histology, primary disease site, the
presence of metastatic disease (liver, bone or brain) and tumour
marker levels at the time ofHDT did not correlate with OS or DFS
in this series of 31 patients. There was a trend (P = 0.06) towards
worse DFS in patients with high tumour marker levels at presenta-
tion (HCG > 10 000 IU 1-', AFP > 1000 kU 1-'). Disease status
before HDT, however, was the only significant prognostic factor
for both OS and DFS (Figure 2). None of ten patients with refrac-
tory relapse have survived disease free (one has been in CR for 11
months after surgical resection of persistent disease post HDT),
while the 3-year probability of OS and DFS in the 21 other patients
(12 with primary refractory disease and 9 with responsive relapse)
was 60% and 42% respectively.
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
---'-- Refractory relapse (n= 10)
--1&- Other (n = 21)
(P < 0.001)
0 1 2 3 4 5 6
Years after HDT
Figure 2 (A) Overall survival and (B) disease-free survival in ten patients
with refractory relapse and 21 patients with either primary refractory disease
or responsive relapse ('others')
Long-term outcome was not significantly influenced by renal
function before HDT (Figure 3). DFS (but not OS) was apparently
better (P < 0.02) in patients who received HDT less than 2 years
after presentation (Figure 4), but of the nine patients in whom this
interval was longer than 2 years six had refractory relapsed disease.
DISCUSSION
In this series of 31 patients with advanced disease the 3-year proba-
bilities of OS and DFS were 41% and 28% respectively; these
outcomes are similar to those that have been reported in comparable
patient groups (Nichols et al, 1992; Siegert et al, 1994; Beyer et al,
1996). The most significant prognostic factor found in this study
was disease status at the time of HDT; patients who had either failed
to achieve an initial CR with first-line therapy or had chemotherapy-
sensitive relapse had a significantly better outcome that those with
resistant relapse. These findings concur with previous studies that
have reported HDT in chemotherapy-responsive patients (Barnett et
al, 1993; Margolin et al, 1996) and in patients with resistant relapse
(Broun et al, 1992; Siegert et al, 1994; Beyer et al, 1996). Of note,
four patients who relapsed after HDT remain in CR at 11-55 months
after either additional conventional chemotherapy/radiotherapy (two
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Figure 3 (A) Overall survival and (B) disease-free survival by pre-HDT Figure 4 (A) Overall survival and (B) disease-free survival by time from
GFR (NS, non-significant) diagnosis to HDT (NS, non-significant)
patients) or surgical resection of residual tumour (two patients).
These data suggest that further therapy may benefit some patients
who have failed salvage intensification.
A significant proportion of patients with GCT considered suit-
able for HDT may have impaired renal function as a result of
either previous nephrotoxic chemotherapy or the effects of
local tumour. In this study, the median GFR before HDT was
75 ml min-', and in 4 of 31 patients the GFR was less than
40 ml min-'. On the assumption that HDT-associated toxicity
might in part be caused by excessive carboplatin exposure, it was
decided to adjust carboplatin dose to measured GFR. While the
median dose received by patients (1.6 g m-2) was similar to other
reports (Nichols et al, 1992; Siegert et al, 1994; Beyer et al, 1996),
the dose range was wide (0.60-2.53 g m-2). The lack of significant
correlation between pre-HDT GFR and eventual outcome could
indicate that these patients received therapy of equivalent efficacy.
Early mortality in previous studies of HDT has ranged from 0%
to 18% (Broun et al, 1992; Rosti et al, 1992; Barnett et al, 1993;
Motzer et al, 1993; Siegert et al, 1994; Margolin et al, 1996), with a
finding of 8% in the largest reported group of 310 patients (Beyer et
al, 1996). In this study HDT-associated death occurred in 1 of 31
patients (3%), as a result of acute renal failure, with two other
patients requiring temporary haemodialysis. Although this was not
a randomized study, these data suggest that adjustment of carbo-
platin dose to renal function may reduce the early morbidity and
mortality associated with HDT without compromising efficacy.
In conclusion, the HDT schedule used in this study appears to
be effective in a significant proportion of patients with primary
refractory or relapsed (but chemotherapy-sensitive) GCT. The
previously noted poor outcome for those with resistant relapse,
confirmed in this study, suggests that altemative therapeutic
approaches should be explored in these patients.
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